Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical firm Akorn has announced that the FDA has granted approval for the company's abbreviated new drug application for ofloxacin ophthalmic solution USP, 0.3%.
Subscribe to our email newsletter
Ofloxacin ophthalmic solution is an anti-infective used to treat infections caused by bacteria in conjunctivitis and corneal ulcers.
Arthur Przybyl, Akorn’s president and CEO, said: “This product will be manufactured in our Decatur, Illinois facility, and represents an important addition to our ophthalmic product line. We expect to launch Ofloxacin in the third quarter of 2008.”